Aug. 23 at 4:51 PM
$IBRX The Personalized Neoantigen Approach: Moderna made massive waves with its landmark Phase 3 melanoma trial results alongside Merck for their personalized mRNA cancer vaccine (intismeran) combined with Keytruda, showing success in hitting recurrence-free survival endpoints.
The Off-the-Shelf vs. Custom Advantage: While personalized vaccines like Moderna's require custom-sequencing a patient's specific tumor mutations (taking time and substantial manufacturing coordination per individual), Ibrx's CAR-NK and Anktiva (nogapendekin alfa inbakicept) platforms are designed as off-the-shelf biological therapies.
Broader Immune Activation: Rather than teaching the body to recognize unique personal neoantigens one patient at a time, Ibrx's approach utilizes IL-15 superagonist mechanics to rapidly expand natural killer (NK) cells and CD8+ T-cells while reversing profound systemic lymphopenia across multiple solid tumors. No 6 week wait , more effective and 90% cheaper. Wild 4th qtr coming*
